Edward McKenna
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Colorectal Cancer Treatments and Studies, Cutaneous Melanoma Detection and Management, Hedgehog Signaling Pathway Studies, Nonmelanoma Skin Cancer Studies
Most-Cited Works
- → Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis(2018)651 cited
- → Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study(2017)407 cited
- → TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab(2011)237 cited
- → Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib(2013)188 cited
- → 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study(2021)174 cited
- → Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials(2014)166 cited
- → Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials(2015)119 cited
- → Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study(2017)99 cited
- → Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma(2018)95 cited
- → Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma(2021)71 cited